A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Universal Ibogaine's Debt-to-EBITDA or its related term are showing as below:
IBOGF's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.14 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Universal Ibogaine Debt-to-EBITDA Related Terms
Universal Ibogaine Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Universal Ibogaine's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IBOGF vs LABT, CALC, LNAI: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Universal Ibogaine's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universal Ibogaine Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Universal Ibogaine's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2025) EBITDA data.
Universal Ibogaine (IBOGF) has a Debt-to-EBITDA of 12.10 as of Apr. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Universal Ibogaine.
Is Universal Ibogaine's Debt-to-EBITDA too high?
Universal Ibogaine's current Debt-to-EBITDA is 12.10. The Biotechnology industry median Debt-to-EBITDA is 1.14. Universal Ibogaine's value of 12.10 is 961.4% above this industry median.
How does Universal Ibogaine's Debt-to-EBITDA compare to LABT and CALC?
Universal Ibogaine's Debt-to-EBITDA of 12.10 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.14. Universal Ibogaine's value of 12.10 is 961.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universal Ibogaine's current Debt-to-EBITDA of 12.10 is 961.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Universal Ibogaine. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universal Ibogaine's current Debt-to-EBITDA is 12.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current Debt-to-EBITDA of 12.10. The current Debt-to-EBITDA is 12.10 and 961.4% above the Biotechnology industry median of 1.14. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current Debt-to-EBITDA is 12.10 as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBOGF has been successfully added to your 